Enzalutamide in metastatic castration-resistant prostate cancer, real-world data

2022 ◽  
Vol 9 (1) ◽  
pp. 738-743
Author(s):  
Aykut Bahçeci ◽  
Ali Murat Sedef ◽  
Gökmen Aktaş ◽  
Polat Olgun ◽  
Havva Yeşil Çınkır ◽  
...  

Objective: Androgen deprivation therapy (ADT) is used alone or in combination with docetaxel or androgen inhibitors in the initial treatment of metastatic prostate cancer (PC) (mPC). Enzalutamide is an androgen receptor inhibitor that is used orally and plays a role in different steps of the androgen receptor (AR) signal pathway. The aim of this study is to determine the real life data of patients using enzalutamide for metastatic PC. Material and Methods: The 118 patients from a totally 6 centers using enzalutamide treatment were included in this retrospective analysis. Clinical information of patients was recorded from patient files or automation records. Results: Median OS was 71 months, and median PFS was five months (4,1 – 5,9 months). There was no association of Gleason score with OS and PFS (p = 0.5 and p = 0.4, respectively). Although those who were metastatic at the time of diagnosis lived longer than those who developed metastases later, the difference was not statistically significant (p = 0.9). Likewise, there was no relationship between the time of metastasis development and PFS (p = 0.2). There was no difference in OS and PFS between patients with visceral metastasis and those without (p = 0.3, p = 0.5, respectively). Conclusion: Enzalutamide is an effective and safe agent in accordance with the literature in the patient group included in this study, although some patients may have an unresponsiveness to enzalutamide or develop progression under the enzalutamide treatment. More studies are needed to understand which patient group can benefit more from enzalutamide.

2020 ◽  
Vol 21 ◽  
pp. S151
Author(s):  
L.F. Sánchez-Cousido ◽  
Á. Rodríguez Sánchez ◽  
M. López Flores ◽  
A. López González ◽  
B. Castañón González ◽  
...  

2019 ◽  
Vol 20 (9) ◽  
pp. 2066 ◽  
Author(s):  
Namrata Khurana ◽  
Suresh C. Sikka

Androgen receptor (AR) signaling plays a key role not only in the initiation of prostate cancer (PCa) but also in its transition to aggressive and invasive castration-resistant prostate cancer (CRPC). However, the crosstalk of AR with other signaling pathways contributes significantly to the emergence and growth of CRPC. Wnt/β-catenin signaling facilitates ductal morphogenesis in fetal prostate and its anomalous expression has been linked with PCa. β-catenin has also been reported to form complex with AR and thus augment AR signaling in PCa. The transcription factor SOX9 has been shown to be the driving force of aggressive and invasive PCa cells and regulate AR expression in PCa cells. Furthermore, SOX9 has also been shown to propel PCa by the reactivation of Wnt/β-catenin signaling. In this review, we discuss the critical role of SOX9/AR/Wnt/β-catenin signaling axis in the development and progression of CRPC. The phytochemicals like sulforaphane and curcumin that can concurrently target SOX9, AR and Wnt/β-catenin signaling pathways in PCa may thus be beneficial in the chemoprevention of PCa.


2017 ◽  
Vol 28 (9) ◽  
pp. 2264-2271 ◽  
Author(s):  
D.E. Rathkopf ◽  
M.R. Smith ◽  
C.J. Ryan ◽  
W.R. Berry ◽  
N.D. Shore ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document